Wednesday, July 17, 8:24 AM ET
UBS thinks data from a Phase III study will "suggest a greater magnitude of overall survival benefit" for Medivation's (MDVN) Xtandi than for Janssen's (JNJ) Zytiga. Analyst Matthew Roden upgrades MDVN to Buy and hikes his price target to $74 from $59.
No comments:
Post a Comment